Form 4: Biogen Director Caroline Dorsa Reports Stock Purchase
SEC Form 4 Filing
Director Caroline Dorsa reported purchasing 1,235 shares of Biogen stock at $122.72 on May 2, 2025.
Summary
- On May 2, 2025, Caroline Dorsa, a director at Biogen Inc., purchased 1,235 shares of Biogen's common stock.
- The purchase price was $122.72 per share.
- Following the transaction, Dorsa directly owns 27,842 shares of Biogen stock.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a stock purchase by a director, which could be interpreted as slightly positive, but without further context, it's difficult to gauge the overall impact.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. These filings are closely watched by investors seeking insights into management's sentiment and confidence in the company's performance.
Stakeholder Impact
- The stock purchase by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/02/2025 | Date of stock purchase transaction |
| 05/05/2025 | Date of signature on the Form 4 filing |
Keywords
Biogen, BIIB, Form 4, insider trading, stock purchase, Caroline Dorsa, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.